Escherichia coli producing CTX-M-2 [beta]-lactamase in Cattle, Japan.

From November 2000 to June 2001, Escherichia coli strains producing CTX-M-2 [beta]-lactamase were isolated from 6 (1.5%) of 396 cattle fecal samples and 2 (0.7%) of 270 surface swabs of cattle carcasses in Japan. The [bla.sub.CTX-M-2] gene responsible for CTX-M-2 production was encoded on transferable plasmids, and the gene was transferred to E. coil CSH2 with a very high frequency (2 x [10.sup.-4] to 6 x [10.sup.-1] per donor cells) by conjugation. Random amplified polymorphic DNA analysis of nine isolates showed at least five different patterns. These findings suggest that CTX-M-2 producers might have originated from cattle through the use of cephalosporins such as ceftiofur and that cattle could be a reservoir of CTX-M-2-producing E. coli. Continuous and strategic surveillance of antimicrobial-resistant bacteria in livestock is essential to suppress further dissemination of these bacteria into society at large.

**********

Shortly after a variety of expanded-spectrum cephalosporins were introduced in the 1980s, bacterial strains producing extended-spectrum [beta]-lactamases (ESBLs), such as TEM- or SHV-derived ESBLs, emerged in Europe (1), and since then, their variants have been proliferating around the world (2,3). More recently, CTX-M-type [beta]-lactamases, a small but growing family of broad-spectrum class A [beta]-lactamases, were initially discovered as MEN-1 (EMBL accession no. X92506) and also later found as Toho-1 in Japan in 1993 (4). Since the early 1990s, these [beta]-lactamases have been identified in various bacterial species belonging to the family Enterobacteriaceae (5). Several questions regarding the origin and mode of proliferation of the CTX-M-type [beta]-lactamases are unclear. Unlike TEM- and SHV-derived ESBL producers, the CTX-M-type [beta]-lactamase producers have been incidentally and sporadically detected as single clinical isolates from patients with urinary tract infections and the like (6,7) over an extensive geographic area, including Europe, South America, and the Middle and Far East. The cause of this global distribution is not well known (5,8). Moreover, derivation of the CTX-M-type enzymes or the prototype of this enzyme with its narrow spectrum remains unknown (9-12).

In Japan, clinical isolation of the TEM- or SHV-derived ESBL producers is still rare (13,14); Escherichia coli strains producing CTX-M-2 [beta]-lactamase, one of the CTX-M family, have been predominantly isolated to date (13). On the other hand, clinical isolates producing IMP-1 type metallo-[beta]-lactamase, which show resistance to carbapenems and cephamycins as well as various expanded-spectrum cephalosporins, have been identified in Japan (15), and the proliferation of these strains has become a clinical concern (16). As for the disproportionately low isolation rate of the TEM- or SHV-derived ESBL producers in Japan, carbapenems and cephamycins, whose use has been restricted in many Western countries, have been preferentially used as first-line drugs in Japan (13,15). This practice makes it more plausible that TEM- or SHV-derived ESBL producers would be rarely isolated and that metallo [beta]-lactamases would be isolated often in Japan. However, it is not easy to explain the predominant isolation of E. coli-producing CTX-M-2 [beta]-lactamase that is usually susceptible to carbapenems and cephamycins like TEM- or SHV-derived ESBL producers. In addition, since CTX-M-2 [beta]-lactamase producers tend to be isolated from patients who have neither received antimicrobial drugs nor been hospitalized, the existence of healthy carriers of CTX-M-2 producers was suspected (17,18). Still, one cannot assume healthy carriers exist on the basis of the low isolation rate of strains producing broad-spectrum class A [beta]-lactamases in Japan.

One hypothesis to address these issues is that CTX-M-2 might have emerged elsewhere than in humans and that the enzyme might have originated in livestock. Recently, a global threat developed because certain antimicrobial-resistant bacteria, such as vancomycin-resistant enterococci (19), Salmonella enterica Typhimurium DT104 (20) and fluoroquinolone-resistant Campylobacter jejuni and C. colt (21) emerged in food animals possibly through the use of antimicrobial drugs for growth promotion or disease treatment. However, few reports have been published about strains in animals producing ESBLs or CMY-type cephamycinases, which confer resistance to expanded-spectrum cephalosporins (22,23), and no CTX-M-type [beta]-lactamase producer has been isolated from animals. Therefore, to examine this hypothesis, we conducted a study to isolate any strains producing extended-spectrum class A [beta]-lactamases from cattle at Japanese slaughterhouses.

Materials and Methods

Sampling and Bacterial Culture

From November 2000 to June 2001, a total of 396 fecal samples of cattle and surface swabs of 270 cattle carcasses were collected at two slaughterhouses in Gifu Prefecture, Japan. ESBL screening agar plates (17), which were prepared using BTB Lactose agar (Nissui Pharmaceutical Co., Tokyo, Ltd., Japan) containing 2 [micro]g/mL of cefotaxime (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) and 8 [micro]g/mL of vancomycin (Shionogi & Co., Ltd., Osaka, Japan), were used to isolate gram-negative enterobacteria that produce broad-spectrum class A [beta]-lactamases. One swab was used to sample each cattle feces, and two swabs were used for each cattle carcass. For sampling of the cattle feces, a swab was inserted into the core of a lump of feces. When several cattle were kept in the same enclosure, a direct rectal swab was sampled from each of the cattle. Shoulder and rump were swabbed separately in each cattle carcass; the size of the swabbed area was approximately 20 x 20-square centimeters for each swab. Swabs of feces were plated directly on the screening agar. Swabs of carcasses were suspended in a 10-mL Trypticase soy broth (Nissui Pharmaceutical Co.) containing 2 [micro]g/mL of cefotaxime and 8 [micro]g/mL of vancomycin, and then plated on the screening agar. The remaining Trypticase soy broth with bacteria was further incubated overnight. A swab of bacterial culture was then plated on the screening agar. Colonies suspected to be enterobacteria were isolated and identified by using the API 20E system (bioMerieux, Marcy l'Etoile, France). E. coli isolates were serotyped with a slide agglutination kit (Denka Seiken Co., Ltd., Tokyo, Japan) and were screened for genes of virulence factors, including Shiga toxins and E. coli attaching and effacing factor by polymerase chain reaction (PCR) (24).

Detection of [beta]-Lactamases

The acidmetric [beta]-lactamase test was performed by using P/Case TEST (Showa Yakuhin Kako Co., Ltd., Tokyo, Japan) to detect [beta]-lactamase production in the isolates. According to the manufacturer's instructions, the colonies were spread on two indicator disks, containing benzylpenicillin and cephaloridine with clavulanic acid, respectively. When the strain produces class A [beta]-lactamases, including TEM- or SHV-derived ESBLs, or CTX-M-type enzymes, the color of a disk containing benzylpenicillin turns yellow. The other disk, containing cephaloridine with clavulanic acid, remains purple because hydrolysis of cephaloridine by the class A [beta]-lactamases is blocked in the presence of clavulanic acid. If the strain produces class C or class B [beta]-lactamases, both disks turn yellow because these enzymes are no longer blocked by clavulanic acid. The isolates suggested to produce extended-spectrum class A [beta]-lactamase were further investigated to determine whether they produced ESBLs by the doubledisk diffusion test (25), using two Kirby-Bauer disks (Eiken Chemical Co., Ltd., Tokyo, Japan). A swab of bacterial culture (approximately [10.sup.6] CFU/mL) to be tested was spread on a Mueller-Hinton agar plate (Eiken Chemical Co.), and one disk containing cefotaxime, ceftazidime, ceftriaxone, cefpodoxime, aztreonam, or cefepime was put on the plate. The other disk, containing amoxicillin+clavulanic acid, was also placed alongside the first disk (center-to-center distance of approximately 3 cm), and the agar plate was then incubated for 18 hours. When an expansion of the inhibitory zone between the two disks was observed, the isolates were speculated to produce ESBL.

Conjugation and Plasmid Profiles

Conjugation experiments were performed by using E. coli CSH2 as a recipient, as previously described (17). A mixture of donor and recipient strains was incubated in Luria-Bertani broth (Difco Laboratories, Detroit, MI) at 37[degrees]C for 18 hours. Transconjugants were selected by using BTB Lactose agar plates supplemented with 100 [micro]g/mL of rifampicin (Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan) and 2 [micro]g/mL of cefotaxime to inhibit the growth of the donor strain and the recipient strain, respectively. Frequency of transfer was calculated by dividing the number of transconjugants by the number of donors. Plasmid DNA was prepared from the isolates and their transconjugants by using Quantum Prep Plasmid Miniprep Kit (Bio-Rad Laboratories, Richmond, CA), according to the manufacturer's instructions. After agarose gel electrophoresis, the sizes of the plasmids were determined by comparing their migration distances with those of plasmids of known sizes.

Susceptibility Testing

MICs were determined by overnight broth-microdilution method using MicroScan ESBL Confirmation Panel (Dade Behring, Sacramento, CA). This panel was designed to detect ESBL producers in accordance with the National Committee for Clinical Laboratory Standards (NCCLS) document M100-S9 (26). The MIC of ceftiofur (Pharmacia Co., Kalamazoo, MI), an expanded-spectrum cephalosporin often used in veterinary medicine, was also determined by the broth-microdilution method in accordance with NCCLS document M7-A4 (27). E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as quality-control strains.

PCR and DNA Sequencing

To determine the genotype of strains producing broad-spectrum class A [beta]-lactamases, PCR was performed by using primers specific to TEM, SHV (13), CTX-M-1 (MEN-1) (28), CTX-M-2 (29), and CTX-M-9 (8) genes. The PCR products were sequenced by using a BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster City, CA) with the same primers for PCR. The DNA sequences were analyzed in an ABI PRISM 377 XL Sequencer Analyzer (Applied Biosystems).

RAPD Analysis

Random amplified polymorphic DNA (RAPD) analysis was performed by using Ready-To-Go RAPD analysis beads (Amersham Pharmacia Biotech, Piscataway, NJ), according to the manufacturer's instructions. DNA was prepared from the isolates using InstaGene DNA Purification Matrix (Bio-Rad Laboratories), also according to the manufacturer's instructions. The reaction mixture contained 25 pmol of one of six RAPD analysis primers (Amersham Pharmacia Biotech) and 10 [micro]L of DNA preparation in a final volume of 25 [micro]L. Amplification was performed with initial denaturation at 95[degrees]C for 5 minutes, followed by 45 cycles of 1 minute at 95[degrees]C, 1 minute at 36[degrees]C, and 2 minutes at 72[degrees]C. The amplified products were separated by electrophoresis in 1.5% agarose gel. The fingerprints were compared visually, and patterns were considered different when they differed by at least one amplification band.

Results

Identification of [beta]-Lactamases

Of 396 fecal samples of cattle, 104 (26.3%) samples gave colonies on the ESBL screening agar. Among the strains grown on the screening agar, 32 strains of E. coli and 2 strains of Citrobacter koseri were positive through the P/Case TEST for production of penicillinase, cephalosporinase, or both (Table 1). The double-disk diffusion test was performed on 28 strains that were speculated to produce penicillinase; 7 strains isolated from 6 (1.5%) of 396 fecal samples were positive. However, two strains, GS553 and GS554, which produced cephalosporinase and penicillinase, showed a clear expansion of the inhibitory zone only when a disk of cefepime, a better detection agent for ESBLs in the presence of an AmpC [beta]-lactamase (30), was used. By a PCR analysis with a set of PCR primers specific for [bla.sub.CTX-M-2], a 900-bp fragment was amplified from the seven strains that were positive in the double-disk diffusion test (Table 1). However, since CTX-M-2 and Toho-1 have only one amino acid substitution, genes for [blac.sub.CTX-M-2] and [bla.sub.Toho-1] were indistinguishable by the PCR. DNA sequencing of the PCR products subsequently showed that all were 100% identical with the [bla.sub.CTX-M-2] reported (31). Similarly, two strains isolated from 2 (0.7%) of 270 surface swab samples of cattle carcasses were positive in the double-disk diffusion test and possessed [bla.sub.CTX-M-2] (Table 1).

Although all 9 isolates producing CTX-M-2 [beta]-lactamase were E. coli, their serotype of O antigen could not be defined with 43 commercially available antisera that were representative serotypes of pathogenic E. coli. Moreover, genes of virulence factors described previously were not detected from the strains by PCR.

Antimicrobial Susceptibility Testing

The susceptibilities of two representative isolates, GS528 and GS554, and their transconjugants are shown in Table 2. All the isolates were resistant to piperacillin, cefotaxime, ceftriaxone, cefpodoxime, cefepime, and aztreonam, and more resistant to cefotaxime than to ceftazidime. Except for strains GS553 and GS554, the [beta]-lactamase inhibitor clavulanic acid (fixed concentration of 4 [micro]g/mL) reduced MICs of cefotaxime and ceftazidime by >[2.sup.10]- and [greater than or equal to] [2.sup.4]-fold, respectively. These susceptibility profiles of the isolates were similar to those observed for strains that produced CTX-M-2 [beta]-lactamase (31). Both GS553 and GS554 strains, which produced cephalosporinase as well as penicillinase, were resistant to cefotetan, cefmetazole, and cefoxitin as well as piperacillin, cefotaxime, ceftriax-one, cefpodoxime, cefepime, and aztreonam. In addition, clavulanic acid hardly reduced the resistance levels of these two strains to cefotaxime and ceftazidime. These results, together with those obtained through the double-disk diffusion test, suggested that both GS553 and GS554 strains produced putative AmpC [beta]-lactamase at high levels as well as the CTX-M-2 [beta]-lactmase. All the isolates producing CTX-M-2 [beta]-lactamase were highly resistant to ceftiofur (MIC >1,024 [micro]g/mL).

Plasmid and RAPD Analysis

Conjugation experiments indicated that all the isolates were able to transfer their cefotaxime resistance to the recipient and that the resistance to cephamycins observed in both strains GS553 and GS554 was also transferred to the transconjugant. All transconjugants produced the same [beta]-lactamase(s) of their donor strains, and susceptibility profiles of the transconjugants were also similar to those of donor strains (Table 2). These results demonstrated that [bla.sub.CTX-M-2] genes of the isolates might be encoded on transferable plasmids. The frequency of transfer was very high (2 x [10.sup.-4] to 6 x [10.sup.-1] per donor cells) (Table 3). Plasmid profiles of the isolates showed one to three large plasmids with five different patterns in each strain, while an approximately 33-MDa plasmid was common among all the strains. Approximately 33-MDa and 50-MDa plasmids were both transferred to recipient cells in all the strains (Table 3). RAPD analysis of a total of nine isolates gave at least five different patterns (Figure, Table 3). Although strains GS553 and GS554 were isolated from the same fecal sample, they differed in RAPD pattern and plasmid profile.

[FIGURE OMITTED]

Discussion

We investigated the cause of the disproportionate emergence of CTX-M-2 [beta]-lactamase and so-called ESBLs, including TEM- or SHV-derived enzymes, in Japan. We isolated E. coli strains producing CTX-M-2 [beta]-lactamase from 6 (1.5%) of 396 fecal samples from cattle and 2 (0.7%) of 270 surface swabs of cattle carcasses. Negative results, however, do not necessarily mean the organisms are absent on the slaughterhouse carcasses because of the limited size of the overall swabbed surface area.

Our findings raised a complex question: Did CTX-M-2 [beta]-lactamase producers initially emerge in cattle or humans? We assume they emerged from cattle. Indeed, we found no direct evidence of transmission of E. coli strains producing CTX-M-2 [beta]-lactamase from cattle to humans, but our results strongly suggested that transmission of the CTX-M-2 producing microorganism might have occurred between cattle and humans. This speculation is supported by the fact that CTX-M-2 [beta]-lactamase-producers isolated from humans in Japan are identified predominantly as E. coli, as was observed in Japanese cattle. According to the survey of ESBLs in human clinical isolates in Japan, Toho-1-type [beta]-lactamase was the most prevalent, and half of the Toho-1-type [beta]-lactamase producers were E. coli (13). Moreover, the Toho-1-type [beta]-lactamases reported in several studies in Japan were later found to be CTX-M-2 by PCR and sequencing analyses. Furthermore, according to the survey of ESBL producers in human stool specimens reported recently in Japan, Toho-1-type [beta]-lactamase-producing enterobacteria were isolated from 2 (0.5%) of 366 specimens (17). Since the survey samples were from 231 inpatients and 135 outpatients with diarrhea, the rate of CTX-M-2 producers in healthy humans in Japan is estimated to be <0.5%. Indeed, by chi-square analysis, the isolation rate (1.5%) of CTX-M-2 producers in cattle feces obtained in our study showed no statistically significant difference from that of ESBL producers in human cases reported previously in Japan (17). However, we speculate that CTX-M-2 producers found in cattle have something to do with those from humans. Many reports substantiate that bacteria can be transmitted from food-producing animals to humans through the food chain, and we found that the surface of cattle carcasses was stained with the CTX-M-2-producing bacteria. Our speculation is also supported by the fact that TEM- or SHV-derived ESBLs have not been detected from livestock so far even in Western countries, where they have been widely detected with a high frequency in various medical institutions. In other words, if transmission of ESBL producers from human to cattle can occur with some frequency, several TEM- or SHV-derived ESBL producers would be isolated also from cattle. However, no such finding has been reported even in Western countries. Thus, prospective investigations should be conducted to understand the current status of E. coli strains that produce CTX-M-enzymes in livestock, especially in those countries where CTX-M-enzymes have been found in humans.

Recently, SHV-12 [beta]-lactamase-producing E. coli was isolated from a dog with recurrent urinary tract infections (22). The origin of the isolate, however, was not known since the treatment with expanded-spectrum cephalosporins was not been recorded. In livestock, although penicillinases such as TEM-1 and TEM-2 have been identified from cattle (23,32-34), pigs (35), and poultry (36), isolation of ESBL producers has not been reported. On the other hand, ceftriaxone-resistant Salmonella isolates, which produce plasmid-mediated AmpC-type [beta]-lactamase such as CMY-2, are proliferating globally (37). Ceftriaxone-resistant Salmonella and E. coli strains have been also isolated from cattle recently in the United States (23,32,33,35). These findings suggest that cattle can serve as an incubator or reservoir of these antimicrobial drug-resistant bacteria. The authors of the U.S. studies suggested that the emergence of the AmpC-mediated cephalosporin resistance may have been a consequence of the use of ceftiofur, the only cephalosporin approved for systemic use in food animals in the United States (23,32,35). Dunne et al. support this hypothesis, indicating that the use of ceftiofur in cattle may have contributed to the emergence of the ceftriaxone-resistant Salmonella because the isolate shows cross-resistance between ceftiofur and ceftriaxone (33). In our study, all the isolates producing CTX-M-2 [beta]-lactamase were also highly resistant to ceftiofur. What antimicrobial agents had been used at Japanese cattle farms where the CTX-M-2 producers were isolated is not well known, since the samples were collected at slaughterhouses. However, ceftiofur was the only expanded-spectrum cephalosporin approved for livestock in Japan when our study was conducted. In addition, the MIC (>1,024 [micro]g/mL) of ceftiofur for CTX-M-2 producers isolated in this study was relatively higher than those (2 to >32 [micro]g/mL) for TEM- or SHV-derived ESBL producers (38) that have been emerging in so many humans. Thus, the emergence of CTX-M-2 [beta]-lactamase--producing E. coli in Japan might also be a consequence of the use of ceftiofur for livestock. However, why CMY-2 type class C [beta]-lactamase is predominantly found in livestock in the United States is not clear. The types of antimicrobial agents and their use for livestock in that country may have contributed to its high prevalence of CMY-2 producers, although no statistical data are available about the differences in usage of antimicrobial agents between the United States and Japan. Continuous and prospective investigations of veterinary usage of the antimicrobial agents as well as surveillance of antimicrobial-resistance seem necessary for preventing the emergence and further proliferation of antimicrobial-resistant bacteria in livestock.

The CTX-M-2 producers were not considered to reflect a clonal expansion of an E. coli strain carrying [bla.sub.CTX-M-2] because five distinct RAPD patterns and plasmid profiles were identified in the nine isolates. These findings suggest that stealthy plasmid-mediated dissemination of [bla.sub.CTX-M-2] gene among E. coli strains might be under way with the continuous consumption of the third-generation cephalosporin for veterinary use. Conjugal transfer of R-plasmid might occur in the intestinal tract, which is the main habitat of ESBL producers (17,39). Both strains GS553 and GS554 were isolated from the same fecal sample and produced the same [beta]-lactamase, but they were different in terms of RAPD analysis and plasmid profile. Frequencies of transfer of the isolates were high (Table 3). These results suggested that conjugal transfer of the R-plasmids also occurred in the intestinal tract of cattle. Therefore, the possibility of further transfer of the resistance profile of E. coli to expanded-spectrum cephalosporins to other pathogenic bacteria such as Salmonella spp. and diarrheagenic E. coli should not be ignored.

The isolates in this study did not correspond to the serotypes of pathogenic E. coli, and they did not possess the virulence factors assayed. However, lack of virulence factors might contribute to subclinical increase of healthy carriers of these strains and might promote their dissemination among both cattle and human. Especially in livestock, environmental contamination and transmission among individual animals by these strains could expand rapidly because of their breeding system. Therefore, CTX-M-2 producers may well be disseminated even further in cattle farms hereafter. Although nosocomial bacteria that produce extended-spectrum class A [beta]-lactamases have thus far been considered to emerge only among in humans, our study suggested that CTX-M-2 producers could potentially emerge in livestock and that cattle might be an original reservoir of CTX-M-2 producers. Therefore, active and continuous surveillance and strategic countermeasures are necessary for antimicrobial-resistant bacteria, including those strains producing such [beta]-lactamases as CTX-M-type, CMY-type (37,40) and metalloenzymes (16) in live stock, especially in countries where these producers have emerged in human populations.

Table 1. Number of [beta]-lactamase producers isolated from cattle (a)

                                  Acidmetric [beta]-
                                    lactamase test

Sample (no.)     Species     Total   PC   PC and CS   CS   PCR typing

Feces (396)    Escherichia    32     7       19       6    7 (CTX-M-2)
                 coli
               Citrobacter     2     2        0       0         0
                 koseri
Swab (b)       E. coli         5     2        2       1    2 (CTX-M-2)
(270)          C. freundii     1     0        1       0         0

(a) PC, penicillinase; CS, cephalosporinase; PCR, polymerase chain
reaction.

(b) Swab, surface swab of cattle carcass.

Table 2. MICs of [beta]-lactams for Escherichia coli strains isolated
from cattle, transconjugants, and recipients (a)

                         MIC ([micro]g/mL) for E. coli strain:

Antimicrobial drug         GS528         CSH2 trGS528    GS554

Piperacillin                >64              >64          >64
Cefotaxime                  >128             >128         >128
Cefotaxime + CLA (b)   [less than or    [less than or      32
                       equal to] 0.12   equal to] 0.12
Ceftazidime                  2                4            32
Ceftazidime + CLA      [less than or    [less than or      16
                       equal to] 0.12   equal to] 0.12
Aztreonam                   >64               64          >64
Ceftriaxone                 >64              >64          >64
Cefpodoxime                 >64              >64          >64
Cefepime                    >32              >32          >32
Cefotetan              [less than or    [less than or     >32
                       equal to] 0.5    equal to] 0.5
Cefmetazole                  1                1           >16
Cefoxitin              [less than or    [less than or     >32
                        equal to] 2      equal to] 2
Meropenem              [less than or    [less than or      8
                       equal to] 0.5    equal to] 0.5
Ceftiofur                  >1,024           >1,024       >1,024

                          MIC ([micro]g/mL) for
                             E. coli strain:

Antimicrobial drug     CSH2 trGS554        CSH2

Piperacillin               >64        [less than or
                                       equal to] 16
Cefotaxime                 >128       [less than or
                                      equal to] 0.5
Cefotaxime + CLA (b)        32        [less than or
                                      equal to] 0.12
Ceftazidime                 32        [less than or
                                      equal to] 0.5
Ceftazidime + CLA           32        [less than or
                                      equal to] 0.12
Aztreonam                   64        [less than or
                                      equal to] 0.5
Ceftriaxone                >64        [less than or
                                      equal to] 0.5
Cefpodoxime                >64        [less than or
                                      equal to] 0.5
Cefepime                   >32        [less than or
                                       equal to] 1
Cefotetan                  >32        [less than or
                                      equal to] 0.5
Cefmetazole                >16              1
Cefoxitin                  >32        [less than or
                                       equal to] 2
Meropenem                   4         [less than or
                                      equal to] 0.5
Ceftiofur                 >1,024      [less than or
                                      equal to] 0.25

(a) E. coli CSH2 trGS528 and trGS554 were transconjugants of
E. coli GS528 and GS554, respectively.

(b) CLA, clavulanic acid at a fixed concentration of 4 [micro]g/mL.

Table 3. Characteristics of CTX-M-2 [beta]-lactamase--producing
Escherichia coli isolated from cattle (a)

                         [beta]-        Plasmid        Transferred
Strain     Source     lactamase (b)   profile (MDa)   plasmid (MDa)

GS528     Feces 1          PC          33, 50, 86        33, 50
GS542     Feces 2          PC          33, 50, 86        33, 50
GS547     Feces 3          PC          33, 50, 86        33, 50
GS553     Feces 4       PC and CS      33, 50, 61        33, 50
GS554     Feces 4       PC and CS        33, 50          33, 50
GS721     Feces 5          PC              33              33
GS733     Feces 6          PC              33              33
GS631    Swab (c) 1        PC            33, 86            33
GS671      Swab 2          PC            33, 86            33

            Frequency       RAPD
Strain     of transfer     pattern

GS528    6 x [10.sup.-4]      A
GS542    2 x [10.sup.-4]      A
GS547    3 x [10.sup.-4]      A
GS553    3 x [10.sup.-1]      B
GS554    2 x [10.sup.-1]      C
GS721    9 x [10.sup.-2]      D
GS733    2 x [10.sup.-1]      D
GS631    5 x [10.sup.-1]      E
GS671    6 x [10.sup.-1]      E

(a) PC, penicillinase; CS, cephalosporinase; RAPD, random amplified
polymorphic DNA.

(b) [beta]-lactamases were detected by acidmetric [beta]-lactamase
test.

(c)Swab, surface swap of cattle carcass.

This work was supported by grant nos. H12-Shinko-19 and H12-Shinko-20 from the Ministry of Health, Labor and Welfare, Japan.

References

(1.) Knothe H, Shah P, Kromery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11:315-7.

(2.) Rasheed JK, Anderson GJ, Queenan AM, Biddle JW, Oliver A, Jacoby GA, et al. TEM-71, a novel plasmid-encoded, extended-spectrum [beta]-lactamase produced by a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2002;46:2000-3.

(3.) Rasheed JK, Anderson GJ, Yigit H, Queenan AM, Domenech-Sanchez A, Swenson JM, et al. Characterization of the extended-spectrum [beta]-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother 2000;44:2382-8.

(4.) Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H. Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A [beta]-lactamase isolated from Echerichia coli. Antimicrob Agents Chemother 1995;39:2269-75.

(5.) Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type [beta]-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000;14:137-42.

(6.) Gniadkowski M, Schneider I, Palucha A, Jangwirth R, Mikiewicz B, Bauernfeind A. Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing [beta]-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. Antimicrob Agents Chemother 1998;42:827-32.

(7.) Bonnet R, Sampaio JL, Labia R, De Champs C, Sirot D, Chanal C, et al. A novel CTX-M [beta]-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob Agents Chemother 2000;44:1936-42.

(8.) Sabate M, Tarrago R, Navarro F, Miro E, Verges C, Barbe J, et al. Cloning and sequence of the gone encoding a novel cefotaxime-hydrolyzing [beta]-lactamase (CTX-M-9) from Escherichia coli in Spain. Antimicrob Agents Chemother 2000;44:1970-3.

(9.) Simarro E, Navarro F, Ruiz J, Miro E, Gomez J, Mirelis B. Salmonella enterica serovar Virchow with CTX-M-like [beta]-lactamase in Spain. J Clin Microbiol 2000;38:4676-8.

(10.) Bradford PA, Yang Y, Sahm D, Grope I, Gardovska D, Storch G. CTX-M-5, a novel cefotaxime-hydrolyzing [beta]-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimicrob Agents Chemother 1998;42:1980-4.

(11.) Nordmann P. Trends in [beta]-lactam resistance among Enterobacteriaceae. Clin Infect Dis 1998;27(Suppl 1):S100-6.

(12.) Hirakata Y. Extended-spectrum [beta]-lactamases (ESBLs) producing bacteria [in Japanese]. Nippon Rinsho 2001;59:694-700.

(13.) Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum [beta]-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 2000;184:53-6.

(14.) Kurokawa H, Yagi T, Shibata N, Shibayama K, Kamachi K, Arakawa Y. A new SHV-derived extended-spectrum [beta]-lactamase (SHV-24) that hydrolyzes ceftazidime through a single-amino-acid substitution (D179G) in the omega-loop. Antimicrob Agents Chemother 2000;44:1725-7.

(15.) Arakawa Y, Ike Y, Nagasawa M, Shibata N, Doi Y, Shibayama K, et al. Trends in antimicrobial-drug resistance in Japan. Emerg Infect Dis 2000;6:572-5.

(16.) Senda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, et al. Multifocal outbreaks of metallo-[beta]-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum [beta]-lactams, including carbapenems. Antimicrob Agents Chemother 1996;40:349-3.

(17.) Komatsu M, Aihara M, Shimakawa K, Yamanaka T, Matsuo S. Detection of extended-spectrum [beta]-lactamases producing Enterobacteriaceae in feces [in Japanese]. Kansenshogaku Zasshi 2000;74:250-8.

(18.) Kawakami S, Ono Y, Yamamoto M, Matumura M, Okamoto R, Inoue M, et al. Extended-spectrum [beta]-lactamase (ESBL) produced by Escherichia coli and Klebsiella pneumoniae isolated from Teikyo University Hospital--the second report. [in Japanese] Kansenshogaku Zasshi 2000;74:24-9.

(19.) Bates J, Jordens Z, Selkon JB. Evidence for an animal origin of vancomycin-resistant enterococci. Lancet 1993;342:490-1.

(20.) Fone DL, Barker RM. Associations between human and farm animal infections with Salmonella typhimurium DT104 in Herefordshire. Commun Dis Rep CDR Rev 1994;4:R136-40.

(21.) Endtz HP, Mouton RP, van der Reyden T, Ruijs GJ, Biever M, van Klingeren B. Fluoroquinolone resistance in Campylobacter spp isolated from human stools and poultry products. Lancet 1990;335:787.

(22.) Teshager T, Dominguez L, Moreno MA, Saenz Y, Torres C, Cardenosa S. Isolation of an SHV-12 [beta]-lactamase-producing Escherichia coli strain from a dog with recurrent urinary tract infections. Antimicrob Agents Chemother 2000;44:3483-4.

(23.) Bradford PA, Petersen PJ, Fingerman IM, White DG. Characterization of expanded-spectrum cephalosporin resistance in E. coli isolates associated with bovine calf diarrhoeal disease. J Antimicrob Chemother 1999;44:607-10.

(24.) Gannon VPJ, D'souza S, Graham T, King RK, Rahn K, Read S. Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains. J Clin Microbiol 1997;35:656-62.

(25.) Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum [beta]-lantamases conferring transferable resistance to newer [beta]-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10:867-78.

(26.) National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement, M100-S9. Wayne (PA): The Committee; 1999.

(27.) National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard M7-A4. Wayne (PA): The Committee; 1997.

(28.) Nakamura T, Uchida S, Heijyo H, Masuda M, Takahashi H, Komatsu M, et al. A SHV-derived extended-spectrum [beta]-lactamase (SHV-12) produced by an Escherichia coli recovered from wound abscess in post operative case with rectal carcinoma [in Japanese]. Kansenshogaku Zasshi 2000;74:112-9.

(29.) Radice M, Gonzalez C, Power P, Vidal MC, Gutkind G. Third-generation cephalosporin resistance in Shigella sonnei, Argentina. Emerg Infect Dis 2001;7:442-3.

(30.) Thomson KS. Controversies about extended-spectrum and AmpC [beta]-lactamases. Emerg Infect Dis 2001;7:333-6.

(31.) Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM. Sequences of [beta]-lactamase genes encoding CTX-M-I (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other [beta]-lactamases. Antimicrob Agents Chemother 1996;40:509-13.

(32.) Fey PD, Safranek TJ, Rupp ME, Dunne EF, Ribot E, Iwen PC, et al. Ceftriaxone-resistant salmonella infection acquired by a child from cattle. N Engl J Med 2000;342:1242-9.

(33.) Dunne EF, Fey PD, Kludt P, Reporter R, Mostashari F, Shillam P, et al. Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC [beta]-lactamase. JAMA 2000;284:3151-6.

(34.) Casin I, Breuil J, Brisabois A, Moury F, Grimont F, Collatz E. Multidrug-resistant human and animal Salmonella typhimurium isolates in France belong predominantly to a DT104 clone with the chromosome- and integron-encoded [beta]-lactamase PSE-1. J Infect Dis 1999;179:1173-82.

(35.) Winokur PL, Brueggemann A, DeSalvo DL, Hoffmann L, Apley MD, Uhlenhopp EK, et al. Animal and human multidrug-resistant, cephalosporin-resistant Salmonella isolates expressing a plasmid-mediated CMY-2 AmpC [beta]-lactamase. Antimicrob Agents Chemother 2000;44:2777-83.

(36.) Kariuki S, Gilks CF, Kimari J, Muyodi J, Waiyaki P, Hart CA. Plasmid diversity of multi-drug-resistant Escherichia coli isolated from children with diarrhoea in a poultry-farming area in Kenya. Ann Trop Med Parasitol 1997;91:87-94.

(37.) Yan JJ, Ko WC, Chiu CH, Tsai SH, Wu HM, Wu JJ. Emergence of ceftriaxone-resistant Salmonella isolates and rapid spread of plasmid-encoded CMY-2-1ike eephalosporinase, Taiwan. Emerg Infect Dis 2003;9:323-8.

(38.) Deshpande L, Pfaller MA, Jones RN. In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum [beta]-lactamase producing strains. Int J Antimicrob Agents 2000;15:271-5.

(39.) Ohkawa T, Yoshinaga M, Ikarimoto N, Miyanohara H, Miyata K, Doi Y, et al. Characterization of Klebsiella pneumoniae and Escherichia coli strains that produce CTX-M-2-type broad spectrum [beta]-lactamase isolated from a child with leukemia. Pediatr Infect Dis J 2002;21:260-2.

(40.) Doi Y, Shibata N, Shibayama K, Kamachi K, Kurokawa H, Yokoyama K, et al. Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 2002;46:2427-34.

Mr. Shiraki is a microbiological specialist in the isolation and identification of pathogenic microorganisms from foods, environments, and clinical samples. His major research interests are epidemiology and the mechanisms of antimicrobial resistance in life-threatening bacteria. He conducts microbiological diagnostic tests of microbial pathogens isolated from clinical institutions and works in the Department of Infectious Diseases, Gifu Prefectural Institute of Health and Environmental Sciences.

Address for correspondence: Yutaka Shiraki, Department of Infectious Diseases, Gifu Prefectural Institute of Health and Environmental Sciences, 1-1 Naka-Fudogaoka, Kakamigahara, Gifu 504-0838, Japan; fax: [phone]; email: [e-mail]

Yutaka Shiraki, * Naohiro Shibata, ([dagger]) Yohei Doi, ([dagger]) and Yoshichika Arakawa ([dagger])

* Gifu Prefectural Office of Meat Inspection, Gifu, Japan; and ([dagger]) National Institute of Infectious Diseases, Tokyo, Japan